The first computer algorithm capable of identifying which tumor cells are driving aggressive cancer growth has been developed ...

This past year, the role of ctDNA testing has expanded to guide treatment decisions for providers and patients with cancer.

The first computer algorithm capable of identifying which tumor cells are driving aggressive cancer growth has been developed by Cancer Research UK-funded scientists from UCL and The Francis Crick ...

By inferring proliferation rates from single-cell genomics, SPRINTER enhances understanding of tumor evolution and identifies ...

This is among the first times a ctDNA assay has been used in a clinical trial of early-stage lung cancer patients to identify those most likely to benefit from further treatment. As such ...

The first computer algorithm capable of identifying which tumor cells are driving aggressive cancer growth has been created.

Broad enrollment criteria appear to have scuttled the trial, which was designed to test whether ctDNA could identify patients ...

GRAIL (GRAL) announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer, or NSCLC, ctDNA Assay in the global TROPION-Lung12 Phase 3 ...

Detections of ctDNA at baseline in patients with HR-positive early breast cancer were associated with larger tumor size.

The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients ...

Of the 1,901 patients who underwent ctDNA testing to determine their eligibility for the trial, 147 (7.7%) had detectable ctDNA and were therefore eligible. Of these patients, 55% had detectable ...